 |
 |
|
 |
 |
Conclusions
Targeting Y90 to lymphoma using a
monoclonal antibody
Higher rate of responses than antibody
alone even in high risk and refractory
disease
Toxicity is predictable and reversible
This experience suggests that
specifically targeting isotopes to tumors
may have application in other cancers